Selective alkylation of βII-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 15, 2008, Pages 7277-7290

  Fortin, Jessica S ^a,b   Côté, Marie France ^a   Lacroix, Jacques ^a   Desjardins, Michel ^a   Petitclerc, Éric ^a,b   C Gaudreault, René ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Alkylation; Aryl chloroethylurea; Cancer; Chemo sensitizers; Radio sensitizers; Selectivity; Thioredoxin 1; II tubulin

Indexed keywords

1 (2 CHLOROACETYL) 3 (3 CYCLOHEXYLPHENYL)UREA; 1 (2 CHLOROACETYL) 3 (4 MORPHOLINOPHENYL)UREA; 1 (2 CHLOROACETYL) 3 PHENYLUREA; 1 (2 CHLOROETHYL) 3 (1,2,3,4 TETRAHYDRO 1,1,4,4 TETRAMETHYLNAPHTHALEN 6 YL)UREA; 1 (2 CHLOROETHYL) 3 (1,2,3,4 TETRAHYDRONAPHTHALEN 6 YL)UREA; 1 (2 CHLOROETHYL) 3 (3 CYCLOHEXYLPHENYL)UREA; 1 (2 CHLOROETHYL) 3 (4 CYCLOHEXYLPHENYL)UREA; 1 (2 CHLOROETHYL) 3 (4 CYCLOPENTYLPHENYL)UREA; 1 (2 CHLOROETHYL) 3 (4 HEXYLPHENYL)UREA; 1 (2 CHLOROETHYL) 3 (4 MORPHOLINOPHENYL)UREA; 1 (2 CHLOROETHYL) 3 (6,7,8,9 TETRAHYDRO 5H BENZO 7 ANNULEN 3 YL)UREA; 1 (2 CHLOROETHYL) 3 PHENYLUREA; 1 (2 CHLOROETHYL) 3 [3 (CYCLOOCTYLOXY)PHENYL]UREA; 1 (2 CHLOROETHYL) 3 [4 (1 ETHYLCYCLOHEXYL)PHENYLUREA; 1 (2 CHLOROETHYL) 3 [4 (1 METHYLCYCLOHEXYL)PHENYL]UREA; 1 (2 CHLOROETHYL) 3 [4 (1 PROPYLCYCLOHEXYL)PHENYL]UREA; 1 (2 CHLOROETHYL) 3 [4 (CYCLOOCTYLOXY)PHENYL]UREA; 1 [3 (4 METHYLCYCLOHEXYLOXY)PHENYL] 3 (2 CHLOROETHYL)UREA; 1 [4 (4 METHYLCYCLOHEXYLOXY)PHENYL] 3 (2 CHLOROETHYL)UREA; 4,5 DIHYDRO N (4 MORPHOLINOPHENYL)OXAZOL 2 AMINE; 4,5 DIHYDRO N PHENYLOXAZOL 2 AMINE; AMINE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BETA TUBULIN; N (3 CYCLOHEXYLPHENYL) 4,5 DIHYDROOXAZOL 2 AMINE; OXAZOLINE DERIVATIVE; THIOREDOXIN 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREA DERIVATIVE;

ALKYLATION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL NUCLEUS; CELL PROLIFERATION; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; COVALENT BOND; DRUG ACTIVITY; DRUG BINDING; DRUG EFFECT; DRUG IDENTIFICATION; HUMAN; HUMAN CELL; MICROTUBULE; OXIDATION REDUCTION REACTION; SUBSTITUTION REACTION;

EID: 48449100892     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.06.028     Document Type: Article

References (44)

1. Gaudreault R.C., Lacroix J., Pagé M., and Joly L.P. J. Pharm. Sci. 77 (1988) 185
2. Gaudreault R.C., Alaoui-Jamali M.A., Batist G., Béchard P., Lacroix J., and Poyet P. Cancer Chemother. Pharmacol. 33 (1994) 489
3. Legault J., Gaulin J.-F., Mounetou E., Ritchot N., Lacroix J., Poyet P., and Gaudreault R.C. Cancer Res. 60 (2000) 985
4. Bouchon B., Chambon C., Mounetou E., Papon J., Miot-Noirault E., Gaudreault R.C., Madelmont J.-C., and Degoul F. Mol. Pharmacol. 68 (2005) 1415
5. Petitclerc E., Deschesnes R.G., Côté M.-F., Marquis C., Janvier R., Lacroix J., Miot-Noirault E., Legault J., Mounetou E., Madelmont J.-C., and Gaudreault R.C. Cancer Res. 64 (2004) 4654
6. Béchard P., Lacroix J., Poyet P., and Gaudreault R.C. Eur. J. Med. Chem. 29 (1994) 963
7. Mounetou E., Legault J., Lacroix J., and Gaudreault R.C. J. Med. Chem. 44 (2001) 694
8. Mounetou E., Legault J., Lacroix J., and Gaudreault R.C. J. Med. Chem. 46 (2003) 5055
9. Deschesnes R.G., Patenaude A., Rousseau J.L., Fortin J.S., Ricard C., Côté M.F., Huot J., Gaudreault R.C., and Petitclerc E. J. Pharmacol. Exp. Ther. 320 (2007) 853
10. Fortin J.S., Lacroix J., Desjardins M., Patenaude A., Petitclerc E., and Gaudreault R.C. Bioorg. Med. Chem. 15 (2007) 4456
11. Borel M., Degoul F., Communal Y., Mounetou E., Bouchon B., Gaudreault R.C., Madelmont J.-C., and Miot-Noirault E. Br. J. Cancer 96 (2007) 1684
12. Miot-Noirault E., Legault J., Cachin F., Mounetou E., Degoul F., Gaudreault R.C., Moins N., and Madelmont J.-C. Invest. New Drugs 4 (2004) 369
13. Patenaude A., Deschesnes R.G., Rousseau J.L., Petitclerc E., Lacroix J., Cote M.F., and Gaudreault R.C. Cancer Res. 67 (2007) 2306
14. Bouchon B., Papon J., Communal Y., Madelmont J.C., and Degoul F. Br. J. Pharmacol. 152 (2007) 449
15. Fortin J.S., Côté M.F., Lacroix J., Patenaude A., Petitclerc E., and Gaudreault R.C. Bioorg. Med. Chem. Lett. 18 (2008) 3526
16. Fortin, J. S.; Côté, M. F.; Lacroix, J.; Petitclerc, E.; C.-Gaudreault, R. Bioorg. Med. Chem. 2008, 16, 7477.
17. Nishinaka Y., Nakamura H., Masutani H., and Yodoi J. Arch. Immunol. Ther. Exp. (Warz.) 49 (2001) 285
18. Powis G., Mustacich D., and Coon A. Free Radic. Biol. Med. 29 (2000) 312
19. Baker A., Payne C.M., Briehl M.M., and Powis G. Cancer Res. 57 (1997) 5162
20. Watson W.H., Chen Y., and Jones D.P. Biofactors 17 (2003) 307
21. Yokomizo A., Ono M., Nanri H., Makino Y., Ohga T., Wada M., Okamoto T., Yodoi J., Kuwano M., and Kohno K. Cancer Res. 55 (1995) 4293
22. Pennington J.D., Wang T.J.C., Nguyen P., Sun L., Bisht K., Smart D., and Gius D. Drug Resist. Updat. 8 (2005) 322
23. Hodges N.J., Smart D., Lee A.J., Lewis N.A., and Chipman J.K. Toxicology 197 (2004) 101
24. Meuillet E.J., Mahadevan D., Berggren M., Coon A., and Powis G. Arch. Biochem. Biophys. 429 (2004) 123
25. Burke A.-G., Callister M.E.J., and Nakamura H. Trends Pharmacol. Sci. 26 (2005) 398
26. Zhao R., and Holmgren A. J. Biol. Chem. 277 (2002) 39456
27. Baker A.F., Dragovich T., Tate W.R., Ramanathan R.K., Roe D., Hsu C.-H., Kirkpatrick D.L., and Powis G. J. Lab. Clin. Med. 147 (2006) 83
28. Webs. Available from: .
29. Galmarini M.C. Curr. Opin. Investig. Drugs 7 (2006) 1108
30. Kirkpatrick D.L., Jimale M.L., King K.M., and Chen T. Eur. J. Med. Chem. 27 (1992) 33
31. Shoemaker R.H. Nat. Rev. Cancer 6 (2006) 813
32. Chen X.P., Liu S., Tang W.X., and Chen Z.W. Biochem. Biophys. Res. Commun. 361 (2007) 362
33. Ueno M., Masutani H., Arai R.J., Yamauchi A., Hirota K., Sakai T., Inamoto T., Yamaoka Y., Yodoi J., and Nikaido T. J. Biol. Chem. 274 (1999) 35809
34. Wei S.J., Botero A., Hirota K., Bradbury C.M., Markovina S., Laszlo A., Spitz D.R., Goswami P.C., Yodoi J., and Gius D. Cancer Res. 60 (2000) 6688
35. Tashiro E., Tsuchiya A., and Imoto M. Cancer Sci. 98 (2007) 629
36. Hartmann RW., and Batzl C. Eur. J. Med. Chem. 27 (1992) 537
37. Kagechika H., Kawachi E., Hashimoto Y., Himi T., and Shudo K. J. Med. Chem. 31 (1988) 2182
38. Carrigan C.N., Bartlett R.D., Esslinger C.S., Cybulski K.A., Tongcharoensirikul P., Bridges R.J., and Thompson C.M. J. Med. Chem. 45 (2002) 2260
39. González-Bobes F., and Fu G.C. J. Am. Chem. Soc. 128 (2006) 5360
40. Doherty E.M., Fotsch C., Bo Y., Chakrabarti P.P., Chen N., Gavva N., Han N., Kelly M.G., Kincaid J., Klionsky L., Liu Q., Ognyanov V.I., Tamir R., Wang X., Zhu J., Norman M.H., and Treanor J.J. J. Med. Chem. 48 (2005) 71
41. Bechard P., Lacroix J., Poyet P., and Gaudreault R.C. Eur. J. Med. Chem. 29 (1994) 963
42. Johnston T.P., McCaleb G.S., Opliger P.S., and Montgomery J.A. J. Med. Chem. 9 (1966) 892
43. Cantarelli G., and Gentili P. Boll. Chim. Farm. 119 (1980) 144
44. Sabourin C., Robert J.-M.H., Robert-Piessard S., Carbonnelle D., and Lang F. J. Enzyme Inhib. Med. Chem. 19 (2004) 459